Oncology Clinical Research and Trials: Immune-Related Toxicities, Treatment Outcomes, and Translational Insights in Cancer Care
Deadline for manuscript submissions:
24 Oct 2026 | Viewed by
4
Impact Factor:
3.899 | Citiescore:
2.4
Share This Special Issue
📧 𝕏 in fSpecial Issue Editors
Special Issue Information
Dear Colleagues,
Cancer remains one of the leading causes of morbidity and mortality worldwide, representing a major public health challenge due to its biological complexity, therapeutic resistance, and heterogeneous clinical outcomes. Despite significant progress in surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, achieving durable responses and minimizing treatment-related toxicity remain critical goals in oncology care.
In recent years, clinical research and trials have transformed cancer management, particularly through the development of immune checkpoint inhibitors and other immunotherapeutic approaches. While these therapies have improved survival in multiple malignancies, they are also associated with a unique spectrum of immune-related adverse events affecting organs such as the skin, lungs, liver, endocrine system, and gastrointestinal tract. Understanding these toxicities is essential for optimizing patient safety and treatment continuity.
Contemporary oncology research is increasingly focused on correlating treatment outcomes with molecular and immunological biomarkers, tumor microenvironment dynamics, and patient-specific factors. Translational studies are providing deeper insights into mechanisms of treatment response and resistance, enabling more precise and individualized cancer therapies. In parallel, real-world evidence and clinical trial data are helping to refine therapeutic strategies, improve survival outcomes, and better manage long-term complications of cancer treatment.
Building on ongoing advances in oncology clinical research, this Special Issue aims to further expand knowledge on cancer treatment outcomes, immune-related toxicities, and translational discoveries that bridge laboratory findings with clinical practice. We welcome original research articles, systematic reviews, meta-analyses, and clinical trial reports that contribute to improving cancer care and patient survival.
We particularly encourage submissions that explore:
- Immune-related adverse events and toxicity management
- Clinical outcomes of immunotherapy and targeted therapies
- Biomarkers for treatment response and resistance
- Tumor microenvironment and translational oncology insights
- Real-world evidence in oncology clinical trials
- Long-term outcomes and survivorship in cancer patients
We invite researchers, oncologists, and clinicians to contribute high-quality manuscripts that will advance understanding and innovation in cancer research and treatment.
Guest Editor
Kalliopi Megari
Manuscript Submission Information
Manuscripts should be submitted online through the journal submission system by registering and logging into the website. Once registered, authors may access the submission portal directly. Submissions are accepted until the stated deadline. All manuscripts that pass initial editorial screening will undergo a rigorous peer-review process.
Accepted articles will be published continuously upon acceptance and will be listed collectively on the Special Issue webpage. We welcome original research articles, comprehensive reviews, and short communications. Authors intending to submit planned papers may send a title and abstract (approximately 250 words) to the Editorial Office for preliminary evaluation.
Submitted manuscripts must be original, not previously published, and not under consideration elsewhere (except conference proceedings). All submissions are subject to a single-blind peer-review process. Detailed author guidelines are available on the Instructions for Authors page.
We encourage authors to ensure clear scientific writing and proper formatting prior to submission. Language editing services may be used to improve manuscript quality if needed.
We look forward to your valuable contributions to this Special Issue.
Keywords
- Oncology; Clinical Research; Clinical Trials; Cancer Care; Immunotherapy; Immune-Related Toxicities; Treatment Outcomes; Translational Oncology; Biomarkers; Tumor Microenvironment; Targeted Therapy; Real-World Evidence; Cancer Immunology
Benefits
Benefits of Publishing in a Special Issue
Publishing in a Special Issue offers several important advantages for authors and researchers, enhancing both the visibility and impact of their scientific work.
Improved focus and ease of navigation:
By grouping articles under a clearly defined thematic area, Special Issues help readers and researchers navigate broad-scope journals more efficiently and locate relevant studies within their field of interest.
Increased visibility and discoverability:
Special Issues significantly improve the reach of published research. Articles featured in them are more easily discovered by the scientific community and often receive higher citation rates compared to standard publications.
Enhanced research networking opportunities:
Contributing to a Special Issue encourages interaction among authors working on related topics, helping to build new collaborations and strengthen professional research networks across institutions and disciplines.
Broader promotional support:
Articles published in Special Issues are frequently highlighted and promoted through the journal’s communication channels, including social media platforms, thereby increasing readership and academic exposure.
Reprint and extended dissemination opportunities:
Selected Special Issues may be republished in book format through MDPI Books, available in both online and print editions, further extending the reach and long-term accessibility of the research.
For additional details regarding Special Issue policies and publication guidelines, please refer to the journal’s official information page.
Published Papers
Coming Soon